JAMES M. DALY

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

ACADIA PHARMACEUTICALS INC

Filing Date	Source Excerpt
2020-04-29	James M. Daly, age 58, has served as a director of our company since January 2016... The following table shows, for the fiscal year ended December 31, 2019, certain information with respect to the compensation of all non-employee directors of the Company during 2019... James M. Daly: Fees Earned or Paid in Cash $70,000, Option Awards $322,439, Total $392,439.
2021-04-30	James Daly 59 Director ... "Fees Earned or Paid in Cash" represents an annual retainer as a Board member of $50,000, an additional retainer as an Audit Committee member (non-chair) of $10,000 and an additional retainer as a Compensation Committee member (non-chair) of $10,000. "Option Awards" includes the fair value of 5,579 stock options granted June 23, 2020 with an exercise price of $52.73. "Stock Awards" includes the fair value of 3,059 restricted stock units granted June 23, 2020. As of December 31, 2020, an aggregate of 59,329 stock options and 3,059 restricted stock units that had been granted to Mr. Daly were outstanding.
2022-04-29	James Daly 60 Director... The following table shows, for the fiscal year ended December 31, 2021, certain information with respect to the compensation of all non-employee directors of the Company during 2021... James Daly Fees Earned or Paid in Cash $70,000, Option Awards $167,690, Stock Awards $159,008, Total $396,698.
2023-05-01	James M. Daly has served as a director of the Company since January 2016. Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from October 2012 to June 2015. Prior to joining Incyte, Mr. Daly worked for Amgen, Inc. for 10 years, holding multiple leadership positions, including Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Previously, he served as Vice President and General Manager of Amgen's Oncology Business Unit. His teams at Amgen were responsible for the successful launch of many products, including Aranesp®, Neulasta®, Vectibix®, Nplate®, Xgeva® and Prolia®. Previously, Mr. Daly spent over 16 years with Glaxo Wellcome/GlaxoSmithKline, where he held roles of increasing responsibility, including Senior Vice President, General Manager, Respiratory and Anti-Infective Business Unit, and led the U.S. launch of Advair®. Mr. Daly currently serves on the boards of directors of argenx SE, Bellicum Pharmaceuticals, Inc., Halozyme Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc. During the past five years, Mr. Daly has served on the board of directors of Chimerix Inc. Mr. Daly earned his B.S. in pharmacy and M.B.A. from the University at Buffalo, The State University of New York. The NCG Committee believes that Mr. Daly is qualified to serve as a member of our board of directors based on his extensive experience as an executive and director of life sciences companies. The following table shows, for the fiscal year ended December 31, 2022, certain information with respect to the compensation of all non-employee directors of the Company during 2022. Mr. Davis, our Chief Executive Officer, does not receive additional compensation for his services as a director. James Daly Fees Earned or Paid in Cash $70,000 Option Awards $156,098 Stock Awards $156,245 All Other Compensation $0 Total $382,343
2024-04-26	James M. Daly has served as a director of the Company since January 2016. Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from October 2012 to June 2015. Prior to joining Incyte, Mr. Daly worked for Amgen, Inc. for 10 years, holding multiple leadership positions, including Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Previously, he served as Vice President and General Manager of Amgen’s Oncology Business Unit. His teams at Amgen were responsible for the successful launch of many products, including Aranesp®, Neulasta®, Vectibix®, Nplate®, Xgeva® and Prolia®. Previously, Mr. Daly spent over 16 years with Glaxo Wellcome/GlaxoSmithKline, where he held roles of increasing responsibility, including Senior Vice President, General Manager, Respiratory and Anti-Infective Business Unit, and led the U.S. launch of Advair®. Mr. Daly currently serves on the boards of directors of Argenx SE and Madrigal Pharmaceuticals, Inc., each public companies. During the past five years, Mr. Daly has served on the boards of directors of Chimerix Inc., Bellicum Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc. Mr. Daly earned his B.S. in pharmacy and M.B.A. from the University at Buffalo, The State University of New York. The NCG Committee believes that Mr. Daly is qualified to serve as a member of our board of directors based on his extensive experience as an executive and director of life sciences companies. The Board has an Audit Committee, a Compensation Committee, a Nominating and Corporate Governance Committee and a Scientific Advisory Committee. The following table provides membership and meeting information for 2023: James M. Daly: Audit Committee, Compensation Committee. The following table shows, for the fiscal year ended December 31, 2023, certain information with respect to the compensation of all non-employee directors of the Company during 2023. James M. Daly: Fees Earned or Paid in Cash $70,000, Option Awards $158,770, Stock Awards $158,983, Total $387,752.

CHIMERIX INC

Filing Date	Source Excerpt
2015-04-29	Mr. Daly is a pharmacist and received his B.S. and M.B.A. degrees from the University of Buffalo, The State University of New York. Our Board of Directors believes that Mr. Daly’s expertise and experience in the biopharmaceutical industry qualifies him to serve on our Board of Directors.
2016-04-28	Mr. Daly is a pharmacist and received his B.S. and M.B.A. degrees from the University of Buffalo, The State University of New York. Our Board of Directors believes that Mr. Daly’s expertise and experience in the biopharmaceutical industry qualifies him to serve on our Board of Directors.
2017-05-01	Mr. Daly is a pharmacist and received his B.S. and M.B.A. degrees from the University of Buffalo, The State University of New York.
2018-04-26	Mr. Daly is a pharmacist and received his B.S. and M.B.A. degrees from the University of Buffalo, The State University of New York.
2019-04-29	Mr. Daly is a pharmacist and received his B.S. and M.B.A. degrees from the University of Buffalo, The State University of New York.
2020-04-28	Listed as a member of the Board Committees but no biography or technical background provided.

HALOZYME THERAPEUTICS, INC.

Filing Date	Source Excerpt
2016-03-23	Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation, a biopharmaceutical company.
2017-03-24	Mr. Daly earned his B.S. in Pharmacy and M.B.A. from the University at Buffalo, The State University of New York.
2018-03-22	Mr. Daly earned his B.S. in Pharmacy and M.B.A. from the University at Buffalo, The State University of New York.
2019-03-22	Mr. Daly is an advisor to a number of biotech companies... Mr. Daly earned his B.S. in Pharmacy and M.B.A. from the University at Buffalo.
2020-03-20	Mr. Daly is an advisor to a number of biotechnology companies. Previously, he served as Executive Vice President and Chief Commercial Officer at Incyte Corporation.
2021-03-26	Mr. Daly earned his B.S. in Pharmacy and M.B.A. from The State University of New York at Buffalo.
2022-03-25	Mr. Daly brings more than 30 years of experience leading U.S. and global pharmaceutical businesses to the Board of Directors.
2023-03-24	Mr. Daly earned a BS degree in Pharmacy and his MBA from the University at Buffalo. He has more than 30 years of experience leading pharmaceutical businesses.
2024-03-15	James M. Daly is listed as a director with no detailed biography or technical skills mentioned.

MADRIGAL PHARMACEUTICALS, INC.

Filing Date	Source Excerpt
2020-04-29	He earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, The State University of New York.
2021-04-30	He earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, The State University of New York.
2022-05-02	Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and also currently serves as a Director of Acadia Pharmaceuticals, argenx SE, Bellicum Pharmaceuticals, and Halozyme Therapeutics.
2023-05-01	Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and also currently serves as a Director of Acadia Pharmaceuticals, argenx SE, Bellicum Pharmaceuticals, and Halozyme Therapeutics. He previously served on the board of directors of Chimerix, Inc. Most recently, Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation, a publicly-held biopharmaceutical company, from 2012 to 2015. Previously, Mr. Daly worked for Amgen, Inc. and held various leadership positions over a 10-year period, including his last role as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier in his career, he spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK), where he held roles of increasing responsibility, including his last role as Senior Vice President, General Manager of the Respiratory and Anti-Infective Business Unit. He earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, The State University of New York.
2024-04-29	Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry.

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22